Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma
Background - The efficacy and safety of teclistamab in patients with RRMM who received ≥3 prior lines of therapy and were triple-class exposed (TCE) are being evaluated in the single-arm, multicohort, phase I/II MajesTEC-1 trial (NCT04557098). We evaluated the comparative effectiveness of teclistama...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
May 2023
|
| In: |
Clinical lymphoma, myeloma & leukemia
Year: 2023, Volume: 23, Issue: 5, Pages: 385-393 |
| ISSN: | 2152-2669 |
| DOI: | 10.1016/j.clml.2023.02.006 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.clml.2023.02.006 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2152265023000617 
|
| Author Notes: | María-Victoria Mateos, Ajai Chari, Saad Z. Usmani, Hartmut Goldschmidt, Katja Weisel, Keqin Qi, Anil Londhe, Sandhya Nair, Xiwu Lin, Lixia Pei, Eric Ammann, Rachel Kobos, Jennifer Smit, Trilok Parekh, Alexander Marshall, Mary Slavcev, Philippe Moreau |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1861125240 | ||
| 003 | DE-627 | ||
| 005 | 20240329080819.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231010s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clml.2023.02.006 |2 doi | |
| 035 | |a (DE-627)1861125240 | ||
| 035 | |a (DE-599)KXP1861125240 | ||
| 035 | |a (OCoLC)1425210687 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mateos, Maria-Victoria |e VerfasserIn |0 (DE-588)1197091629 |0 (DE-627)1678922323 |4 aut | |
| 245 | 1 | 0 | |a Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma |c María-Victoria Mateos, Ajai Chari, Saad Z. Usmani, Hartmut Goldschmidt, Katja Weisel, Keqin Qi, Anil Londhe, Sandhya Nair, Xiwu Lin, Lixia Pei, Eric Ammann, Rachel Kobos, Jennifer Smit, Trilok Parekh, Alexander Marshall, Mary Slavcev, Philippe Moreau |
| 264 | 1 | |c May 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 3. März 2023, Artikelversion: 17. April 2023 | ||
| 500 | |a Gesehen am 10.10.2023 | ||
| 520 | |a Background - The efficacy and safety of teclistamab in patients with RRMM who received ≥3 prior lines of therapy and were triple-class exposed (TCE) are being evaluated in the single-arm, multicohort, phase I/II MajesTEC-1 trial (NCT04557098). We evaluated the comparative effectiveness of teclistamab versus physician's choice (PC) of therapy in TCE RRMM patients. - Methods - Individual patient-level data from MajesTEC-1 patients who received teclistamab (1.5 mg/kg weekly; clinical cutoff March 16, 2022) were included. An external control arm was created from patients in long-term follow-up of 4 clinical trials of daratumumab who were treated with PC therapy after discontinuation of trial treatments. In the primary analysis, inverse probability of treatment weighting was used to adjust for imbalances in 9 baseline covariates. A fully adjusted model included 5 additional prognostic factors. Outcomes included overall response rate (ORR), very good partial response or better (≥VGPR) rate, overall survival (OS), progression-free survival (PFS), and time to next treatment (TTNT). - Results - After adjustment, baseline characteristics were balanced between cohorts. In the primary analysis, outcomes were significantly improved with teclistamab versus PC: ORR (OR [95% CI] 4.81 [3.04-7.72]; P < .0001); ≥VGPR rate (OR, 12.07 [6.91-22.11]; P < .0001); OS (HR, 0.54 [0.40-0.73]; P < .0001); PFS (HR, 0.59 [0.46-0.78]; P = .0001); and TTNT (HR, 0.32 [0.24-0.42]; P < .0001). Results of the fully adjusted model were consistent with the primary analysis. - Conclusion - Teclistamab showed significantly improved effectiveness versus PC on all outcomes, highlighting its clinical benefit in patients with TCE RRMM and limited treatment options. | ||
| 650 | 4 | |a B-cell maturation antigen | |
| 650 | 4 | |a Bispecific antibody | |
| 650 | 4 | |a Comparative effectiveness | |
| 650 | 4 | |a Indirect treatment comparison | |
| 650 | 4 | |a MajesTEC-1 | |
| 700 | 1 | |a Chari, Ajai |e VerfasserIn |4 aut | |
| 700 | 1 | |a Usmani, Saad Z. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Weisel, Katja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Qi, Keqin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Londhe, Anil |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nair, Sandhya |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lin, Xiwu |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pei, Lixia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ammann, Eric |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kobos, Rachel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Smit, Jennifer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Parekh, Trilok |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marshall, Alexander |e VerfasserIn |4 aut | |
| 700 | 1 | |a Slavcev, Mary |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moreau, Philippe |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lymphoma, myeloma & leukemia |d Amsterdam [u.a.] : Elsevier, 2010 |g 23(2023), 5 vom: Mai, Seite 385-393 |h Online-Ressource |w (DE-627)620142014 |w (DE-600)2540998-0 |w (DE-576)358408776 |x 2152-2669 |7 nnas |a Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:5 |g month:05 |g pages:385-393 |g extent:9 |a Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.clml.2023.02.006 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2152265023000617 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20231010 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 999 | |a KXP-PPN1861125240 |e 4383170129 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"id":{"issn":["2152-2669"],"zdb":["2540998-0"],"eki":["620142014"]},"recId":"620142014","physDesc":[{"extent":"Online-Ressource"}],"disp":"Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myelomaClinical lymphoma, myeloma & leukemia","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["10.2010 -"],"note":["Gesehen am 04.02.20"],"origin":[{"dateIssuedKey":"2010","publisher":"Elsevier ; CIG Media Group","dateIssuedDisp":"2010-","publisherPlace":"Amsterdam [u.a.] ; Dallas, Tex."}],"title":[{"title_sort":"Clinical lymphoma, myeloma & leukemia","title":"Clinical lymphoma, myeloma & leukemia"}],"part":{"volume":"23","extent":"9","text":"23(2023), 5 vom: Mai, Seite 385-393","issue":"5","pages":"385-393","year":"2023"},"titleAlt":[{"title":"Clinical lymphoma, myeloma and leukemia"}],"language":["eng"]}],"recId":"1861125240","name":{"displayForm":["María-Victoria Mateos, Ajai Chari, Saad Z. Usmani, Hartmut Goldschmidt, Katja Weisel, Keqin Qi, Anil Londhe, Sandhya Nair, Xiwu Lin, Lixia Pei, Eric Ammann, Rachel Kobos, Jennifer Smit, Trilok Parekh, Alexander Marshall, Mary Slavcev, Philippe Moreau"]},"physDesc":[{"noteIll":"Illustrationen","extent":"9 S."}],"id":{"eki":["1861125240"],"doi":["10.1016/j.clml.2023.02.006"]},"note":["Online verfügbar: 3. März 2023, Artikelversion: 17. April 2023","Gesehen am 10.10.2023"],"origin":[{"dateIssuedDisp":"May 2023","dateIssuedKey":"2023"}],"title":[{"title":"Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma","title_sort":"Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"person":[{"display":"Mateos, Maria-Victoria","family":"Mateos","given":"Maria-Victoria","role":"aut"},{"family":"Chari","display":"Chari, Ajai","role":"aut","given":"Ajai"},{"given":"Saad Z.","role":"aut","family":"Usmani","display":"Usmani, Saad Z."},{"display":"Goldschmidt, Hartmut","family":"Goldschmidt","role":"aut","given":"Hartmut"},{"given":"Katja","role":"aut","display":"Weisel, Katja","family":"Weisel"},{"display":"Qi, Keqin","family":"Qi","role":"aut","given":"Keqin"},{"role":"aut","given":"Anil","family":"Londhe","display":"Londhe, Anil"},{"role":"aut","given":"Sandhya","family":"Nair","display":"Nair, Sandhya"},{"family":"Lin","display":"Lin, Xiwu","given":"Xiwu","role":"aut"},{"family":"Pei","display":"Pei, Lixia","role":"aut","given":"Lixia"},{"given":"Eric","role":"aut","family":"Ammann","display":"Ammann, Eric"},{"family":"Kobos","display":"Kobos, Rachel","given":"Rachel","role":"aut"},{"given":"Jennifer","role":"aut","family":"Smit","display":"Smit, Jennifer"},{"given":"Trilok","role":"aut","family":"Parekh","display":"Parekh, Trilok"},{"role":"aut","given":"Alexander","family":"Marshall","display":"Marshall, Alexander"},{"role":"aut","given":"Mary","display":"Slavcev, Mary","family":"Slavcev"},{"display":"Moreau, Philippe","family":"Moreau","given":"Philippe","role":"aut"}]} | ||
| SRT | |a MATEOSMARICOMPARATIV2023 | ||